Long-Term Safety and Efficacy of Subretinal Gene Therapy for CNGA3–Associated Achromatopsia
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The British Journal of Ophthalmology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Three-Year Results of Phase 1 Retinal Gene Therapy Trial for CNGA3-Mutated Achromatopsia: Results of a Non-Randomised Controlled Trial
Br J Ophthalmol 2021 May 18;[EPub Ahead of Print], FF Reichel, S Michalakis, B Wilhelm, D Zobor, R Muehlfriedel, S Kohl, N Weisschuh, V Sothilingam, L Kuehlewein, N Kahle, I Seitz, F Paquet-Durand, SH Tsang, P Martus, T Peters, M Seeliger, KU Bartz-Schmidt, M Ueffing, E Zrenner, M Biel, B Wissinger, D FischerFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.